aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
14 avr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting
09 avr. 2021 08h00 HE
|
aTyr Pharma, Inc.
Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with...
aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor
08 avr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update
23 mars 2021 16h05 HE
|
aTyr Pharma, Inc.
Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. Results from ATYR1923 clinical trial in patients with COVID-19 severe...
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results
16 mars 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
15 mars 2021 08h00 HE
|
aTyr Pharma, Inc.
Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings...
aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
11 mars 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor
10 mars 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at March Investor Conferences
25 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces New tRNA Synthetase Discovery Programs
11 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 ...